CASE REPORT article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1453496
Heterozygous ADAR c.3019G>A pathogenic variant associated with variable neurological symptoms and incomplete penetrance in a fourgenerational family
Provisionally accepted- 1Institute of Medical Genetics, Carl von Ossietzky Universität Oldenburg, Oldenburg, Lower Saxony, Germany
- 2Department of Neuropediatrics, University Children’s Hospital, Klinikum Oldenburg, Oldenburg, Lower Saxony, Germany
- 3Institute of Radiology and Neuroradiology, Evangelisches Krankenhaus Oldenburg, Medical Campus, Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany
- 4Department of Paediatrics, Faculty of Medicine Carl Gustav Carus, School of Medicine, Technical University Dresden, Dresden, Lower Saxony, Germany
- 5Institute of Human Genetics, University Hospital Tübingen, Tübingen, Germany
- 6Institute of Diagnostic and Interventional Radiology, Klinikum Oldenburg, Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Heterozygous pathogenic variants in ADAR have been associated with dyschromatosis symmetrica hereditaria, while biallelic pathogenic variants have been associated with Aicardi-Goutières syndrome 6 (AGS6). However, the heterozygous variant c.3019G>A, (p.Gly1007Arg) has been described to cause neurological manifestations, which resemble AGS6 and are associated with an upregulation of interferon-stimulated genes.We report a four-generation family with two symptomatic family members and five unaffected carriers of the heterozygous pathogenic ADAR variant c.3019G>A. The index (patient 1) manifested a gait disorder at three years of age (weakness in his legs, a tendency to fall and hyperreflexia), dyslalia, and mild cognitive developmental delay. A paternal half-brother (patient 4) to patient´s father (patient 2) presented with irritability and regression of previous skills at the age of 6 months after a fever reaction, following the second routine hexavalent vaccination at the age of 4 months. At 20 years of age, the patient was wheelchair-bound, had spasticity and severe global development delay. A blood test in both patients showed increased interferon signature with activation of type 1-interferon. Five asymptomatic carriers were identified in this family (age range 2-81 years of age) nearly all of them (except the 81year old patient) showed a strong activation of type 1 interferon response in peripheral blood. Affected individuals had higher interferon signature than asymptomatic, underlining the possible role of interferon activation in disease mechanism.To our knowledge, this is the biggest family reported to date, encompassing a wide age-range of carriers, including an asymptotic carrier of advanced age (81 years of age).
Keywords: ADAR, c.3019G>A, Aicardi-Goutières syndrome, interferon signature, Dystonia, Spasticity, Reduced penetrance
Received: 23 Jun 2024; Accepted: 30 Jun 2025.
Copyright: © 2025 Bauer, Marquardt, Sundermann, Wolf, Raupach, Grundmann-Hauser, Gieldon, Otterbach, Maurer, Haack, Lee-Kirsch, Korenke and Hitz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ann-Kathrin Bauer, Institute of Medical Genetics, Carl von Ossietzky Universität Oldenburg, Oldenburg, Lower Saxony, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.